
Ipca Laboratories Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3See what Ipca Laboratories management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Ipca Laboratories management said on order book — free account, 30 seconds.
Capex plans
Yes- No direct mention of specific current or future capex or strategic investment plans is found on page 18 or surrounding pages.
- The discussion mainly focuses on business performance, revenue guidance, subsidiaries' progress, product launches, and market growth.
- Subsidiaries like Trophic Wellness and Onyx Scientific are growing steadily, with Pisgah anticipated to improve.
- Launch of 6-7 molecules in the U.S. in the current financial year is on track, which implies ongoing investment in product development.
- There is mention of continued R&D investment around 3% to 4% of turnover, expected to increase to about 4.25% to 4.5% next financial year due to biotech work and clinical batches.
- No explicit capital expenditure figures or major strategic capital investments discussed in this transcript excerpt.
Track Ipca Laboratories — get its next earnings analysis in your feed
How does Ipca Laboratories rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Ipca Laboratories rank in Pharmaceuticals & Biotechnology?
Compare Ipca Laboratories against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Ipca Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem